Transforming lives with safer, more effective therapies.
Preliminary Clinical Pharmacokinetics and Dose-Response to Support a Phase 2 Dose Selection for CX-2009: A Masked PROBODY Drug Conjugate to CD166
Mark Stroh, Rachel Li, Hong Lu, Russ Wada, Jennifer Richardson, Amy Peterson. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.